Figure 7 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity

<p>Pharmacologic inhibition of TDO2/IDO1 or <i>TDO2</i> KD reduces the EMT signature. <b>A–C,</b> GSEA was performed to analyze RNA-seq data from BT549 treated with AT-0174 or vehicle (AT-0174 vs. vehicle) for 48 hours, and BT549 with <i>TDO2</i> KD [sh<i>TDO2</i>-82 vs. shSCR and sh<i>TDO2</i>-98 (IDO1 comp) vs. sh<i>TDO2</i>-82], with biological triplicate for each condition. Significant pathways (<i>P</i> adj. < 0.05) with negative (blue) and positive (red) NES for the hallmark of EMT genes are shown. <b>D</b> and <b>E,</b> Heatmaps of the EMT gene subset from RNA-seq data with <i>z</i>-score-transformed CPM. <b>F</b> and <b>G,</b><i>VIM</i> and <i>CDH2</i> mRNA as by qPCR following AT-0174 treatment for 48 hours. Data are displayed as mean ± SD with <i>t</i> test or one-way ANOVA analysis. *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; ***, <i>P</i> < 0.001; ****, <i>P</i> < 0.0001. <i>CDH2</i>, <i>N</i>-<i>cadherin</i>; CPM, counts per million; NES, normalized enrichment score; <i>VIM</i>, <i>vimentin</i>.</p>